Gilead and the Elton John AIDS Foundation Announce Additional Five Years of RADIAN Partnership to Help Address the Growing HIV Crisis in Eastern Europe and Central Asia
Gilead Sciences (GILD) and the Elton John AIDS Foundation have extended their RADIAN partnership for five more years, investing $25 million to address the growing HIV crisis in Eastern Europe and Central Asia (EECA). The initiative aims to support local organizations and expand its geographic focus to help communities impacted by the Ukraine conflict. RADIAN has already reached over 271,000 people with HIV services and provided more than 114,000 HIV tests since 2019. The partnership will continue to tackle structural drivers of the epidemic, strengthen HIV health systems, and enhance local organizations' capacities. It will also introduce an innovation fund to support creative solutions in the region.
Gilead Sciences (GILD) e l'Elton John AIDS Foundation hanno esteso la loro partnership RADIAN per altri cinque anni, investendo 25 milioni di dollari per affrontare la crescente crisi dell'HIV nell'Europa orientale e in Asia centrale (EECA). L'iniziativa mira a supportare le organizzazioni locali ed espandere il suo focus geografico per aiutare le comunità colpite dal conflitto ucraino. RADIAN ha già raggiunto oltre 271.000 persone con servizi per l'HIV e ha fornito più di 114.000 test dell'HIV dal 2019. La partnership continuerà a affrontare le cause strutturali dell'epidemia, rafforzare i sistemi sanitari per l'HIV e migliorare le capacità delle organizzazioni locali. Sarà inoltre introdotto un fondo per l'innovazione per sostenere soluzioni creative nella regione.
Gilead Sciences (GILD) y la Elton John AIDS Foundation han extendido su asociación RADIAN por cinco años más, invirtiendo 25 millones de dólares para abordar la creciente crisis del VIH en Europa del Este y Asia Central (EECA). La iniciativa tiene como objetivo apoyar a las organizaciones locales y expandir su enfoque geográfico para ayudar a las comunidades afectadas por el conflicto en Ucrania. RADIAN ya ha alcanzado más de 271,000 personas con servicios de VIH y ha proporcionado más de 114,000 pruebas de VIH desde 2019. La asociación continuará enfrentando los factores estructurales de la epidemia, fortalecerá los sistemas de salud del VIH y mejorará las capacidades de las organizaciones locales. También se introducirá un fondo de innovación para apoyar soluciones creativas en la región.
길리어드 사이언스(GILD)와 엘튼 존 에이즈 재단은 RADIAN 파트너십을 5년 더 연장하며 동유럽 및 중앙 아시아(EECA)에서 증가하는 HIV 위기에 대응하기 위해 2,500만 달러를 투자했습니다. 이 이니셔티브는 지역 단체를 지원하고 우크라이나 갈등의 영향을 받는 지역 사회를 돕기 위해 지리적 초점을 확장하는 것을 목표로 합니다. RADIAN은 이미 2019년 이후 271,000명 이상에게 HIV 서비스를 제공하고 114,000개 이상의 HIV 검사를 실시했습니다. 이 파트너십은 전염병의 구조적 원인을 해결하고 HIV 건강 시스템을 강화하며 지역 단체의 역량을 향상시키기 위해 계속 진행될 것입니다. 또한 이 지역에서 창의적인 솔루션을 지원하기 위한 혁신 기금도 도입될 것입니다.
Gilead Sciences (GILD) et la Fondation Elton John contre le sida ont étendu leur partenariat RADIAN pour cinq années supplémentaires, en investissant 25 millions de dollars pour répondre à la crise croissante du VIH en Europe de l'Est et en Asie centrale (EECA). L'initiative vise à soutenir les organisations locales et à élargir son champ géographique pour aider les communautés touchées par le conflit en Ukraine. Depuis 2019, RADIAN a déjà atteint plus de 271 000 personnes avec des services liés au VIH et a effectué plus de 114 000 tests du VIH. Le partenariat continuera à s'attaquer aux causes structurelles de l'épidémie, à renforcer les systèmes de santé liés au VIH et à améliorer les capacités des organisations locales. Un fonds d'innovation sera également introduit pour soutenir des solutions créatives dans la région.
Gilead Sciences (GILD) und die Elton John AIDS Foundation haben ihre RADIAN-Partnerschaft um weitere fünf Jahre verlängert und investieren 25 Millionen Dollar, um der wachsenden HIV-Krise in Osteuropa und Zentralasien (EECA) entgegenzuwirken. Die Initiative zielt darauf ab, lokale Organisationen zu unterstützen und den geografischen Fokus zu erweitern, um den von dem Konflikt in der Ukraine betroffenen Gemeinschaften zu helfen. RADIAN hat bereits über 271.000 Menschen mit HIV-Diensten erreicht und seit 2019 mehr als 114.000 HIV-Tests durchgeführt. Die Partnerschaft wird weiterhin die strukturellen Ursachen der Epidemie angehen, die HIV-Gesundheitssysteme stärken und die Kapazitäten lokaler Organisationen ausbauen. Zudem wird ein Innovationsfonds eingerichtet, um kreative Lösungen in der Region zu unterstützen.
- Extended partnership with $25 million investment over 5 years
- Expansion of geographic focus to include countries hosting Ukrainian refugees
- Introduction of an innovation fund for creative HIV response solutions
- Reached over 271,000 people with HIV services since 2019
- Provided more than 114,000 HIV tests since 2019
- HIV epidemic in EECA region is worsening, with new diagnoses up 20% since 2010
- 41% of people with HIV in EECA are unaware of their status
- 50% of people with HIV in EECA are not on treatment
Gilead's extension of the RADIAN partnership reflects its enduring commitment to addressing pressing health crises in regions with significant HIV challenges. This five-year,
For investors, this development showcases Gilead's proactive approach in managing corporate social responsibility while potentially opening up new avenues for market penetration. The extension might not directly impact short-term financials but demonstrates long-term operational foresight and ethical alignment, factors that can uplift investor sentiment and share value over time.
The RADIAN partnership's expansion is important in addressing the escalating HIV crisis in the EECA region. The initiative's focus on training frontline workers, improving HIV testing and expanding antiretroviral therapy is aligned with global health targets but tailored to local needs. The initiative's reach, impacting over 271,000 people, underscores the potential for significant public health outcomes.
From a medical research perspective, these efforts can catalyze data collection and innovation in HIV treatment strategies, particularly in conflict-impacted and underserved areas. The introduction of an innovation fund within RADIAN further supports the development of creative solutions, which could lead to breakthroughs in HIV care and management, benefiting both the local populations and global health knowledge.
Gilead's increased involvement in the EECA region through the RADIAN partnership reflects a strategic expansion into geographies facing significant health challenges. The extension and the allocation of
For the market, Gilead's actions could set a precedent for other pharmaceutical companies, highlighting the importance of corporate social responsibility in emerging markets. The geographic expansion into areas hosting Ukrainian refugees adds a layer of humanitarian response, showcasing Gilead's adaptability and commitment to addressing emergent health crises. This strategic positioning is likely to increase investor confidence in Gilead's long-term stability and ethical governance.
– RADIAN’s Five-Year,
– RADIAN Will Expand Geographic Focus to Provide Key Populations and Communities Impacted by the Conflict in
![Anne Aslett (CEO, Elton John AIDS Foundation) and Daniel O'Day (Chairman and CEO, Gilead Sciences) visit RADIAN Model City in Kazakhstan. (Photo: Business Wire)](https://mms.businesswire.com/media/20240718867405/en/2190234/4/RADIAN4869.jpg)
Anne Aslett (CEO, Elton John AIDS Foundation) and Daniel O'Day (Chairman and CEO, Gilead Sciences) visit RADIAN Model City in
While HIV is declining globally, EECA is one of the few regions in the world where the epidemic is getting worse, with new HIV diagnoses and AIDS-related deaths increasing by
“We are committed to ensuring that the EECA region is not left behind because ending the HIV epidemic means ending it for everyone, everywhere,” said Daniel O’Day, Chairman and Chief Executive Officer, Gilead Sciences. “During a recent visit to
Since RADIAN was launched in 2019 it has had a significant impact on the HIV response in the region, reaching more than 271,000 people with HIV services, providing over 114,000 HIV tests, (re-) initiating over 26,500 people on antiretroviral therapy, and training more than 14,000 frontline workers to reduce stigma and discrimination.2 These efforts are having an impact on communities most in need, however the situation in the region has escalated dramatically in recent years with the conflict in
“At the Elton John AIDS Foundation, we have a long history of supporting people living with or at risk of HIV across
Over the next five years, RADIAN will extend its efforts to support collaborative, community-based initiatives to help meet the needs of the most vulnerable key populations across EECA, including people who use drugs, men who have sex with men, sex workers and Transgender people.
RADIAN will also expand its geographic reach to include countries hosting refugees fleeing
RADIAN will continue to build on successes and learnings from the first five years of the partnership to help close gaps in HIV testing, prevention and care. Additionally, to support innovations that increase the effectiveness of the HIV response in EECA, RADIAN will introduce an innovation fund. The fund will accept creative applications on a rolling basis to allow for flexibility of funding opportunities as innovations emerge.
About RADIAN
RADIAN is a ground-breaking partnership between Gilead Sciences and the Elton John AIDS Foundation that supports grassroots organizations and partners in
To learn more about how RADIAN is working to end HIV in EECA, visit www.radianhiv.org.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in
For 35 years, Gilead has been a leading innovator in the field of HIV, driving advances in treatment, prevention and cure research. Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly. Our advances in medical research have helped to transform HIV into a treatable, preventable, chronic condition for millions of people.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
About Elton John AIDS Foundation
The Elton John AIDS Foundation was established in 1992 and is one of the leading independent AIDS organizations in the world. The Foundation's mission is simple: an end to the AIDS epidemic. The Elton John AIDS Foundation is committed to overcoming the stigma, discrimination and neglect that keep us from ending AIDS. With the mobilization of our network of generous supporters and partners, we fund local experts across four continents to challenge discrimination, prevent infections, and provide treatment as well as influencing governments to end AIDS. www.eltonjohnaidsfoundation.org
1 Data provided by UNAIDS (2024), https://www.unaids.org/en
2 Data provided by the Elton John AIDS Foundation – June 2024
3 Jonas, Kai J. et al. The war refugees from
4 Schweitzer AM et al, Addressing HIV stigma in healthcare, community, and legislative settings in Central and
5 European Centre for Disease Prevention and Control, Migrant health: HIV testing and counselling in migrant populations and ethnic minorities in EU/EEA/EFTA Member States. Available at: https://www.ecdc.europa.eu/sites/default/files/media/en/publications/Publications/1108_TER_HIV_in_migrants.pdf, last accessed July 2024.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718867405/en/
Meaghan Smith, Media
public_affairs@gilead.com
Jacquie Ross, Investors
investor_relations@gilead.com
Source: Gilead Sciences, Inc.
FAQ
What is the RADIAN partnership between Gilead (GILD) and the Elton John AIDS Foundation?
How much is Gilead (GILD) investing in the RADIAN partnership extension?
What are the main goals of the RADIAN partnership extension for Gilead (GILD)?